US15102K1007 - Common Stock
CELC stock results show that Celcuity beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Celcuity (NASDAQ:CELC) just reported results for the fourth quarter of 2023.Cel...
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant...
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...
MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...
Stifel has initiated coverage of Celcuity (CELC) with a buy rating, stating that the company’s drug gedatolisib has “blockbuster potential.” The investment firm
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...
MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract accepted for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2023 San Antonio Breast Cancer Symposium (SABCS) is being held virtually and in-person from December 5-9, 2023.
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...
MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today reported financial results for the third quarter ended September 30, 2023 and provided other recent corporate updates.
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...
Celcuity (CELC) plans to conduct a private placement offering to raise $50 million, with net proceeds going towards clinical development and corporate...
Explore the potential of the best short-squeeze stocks to buy now as companies attempt to prove pessimistic traders wrong.
Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in...
Although the concept of short-squeeze stocks is one best left for speculators, these ideas have a touch of rationality behind them.
MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...
- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. –...
Phase 3 VIKTORIA-1 clinical trial is now recruiting patients at nearly 200 sites in 20 countriesPresented updated results from Phase 1b study of...
MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted...
MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted...
Celcuity (CELC) reported updated data from a phase 1b trial of gedatolisib ombination treatment for breast cancer. Read more here
Celcuity press release (CELC): Q4 GAAP EPS of -$0.69 misses by $0.25.At December 31, 2022, Celcuity had cash, cash equivalents and short-term investments of $168.6 million.